15 Mechanical overloading is a major cause of tendinopathy, but the underlying pathogenesis of 16 tendinopathy is unclear. Here we report that high mobility group box1 (HMGB1) is released to 17 the tendon extracellular matrix and initiates an inflammatory cascade in response to mechanical 18 overloading in a mouse model. Moreover, administration of glycyrrhizin (GL), a naturally 19 occurring triterpene and a specific inhibitor of HMGB1, the tendon's inflammatory reactions.
HMGB1-alginate beads implantation in tendon in vivo
To assess the function of HMGB1 in vivo, we developed a system to deliver HMGB1 into 145 tendons in vivo to mimic long term release of HMGB1 induced by repetitive mechanical loading. 146 Our delivery system consisted of a degradable polymer called alginate that contained HMGB1 to 147 ensure local and continuous delivery of HMGB1 to maximize the effect in a relatively short 148 period of time.
149 150 A 2% alginate solution was first prepared by dissolving alginate powder (Cat # 180947-151 100G, Sigma-Aldrich) in double distilled water with vigorous vortexing. Then, HMGB1 powder 152 (Cat # H4652, Sigma-Aldrich) was added to the 2% alginate solution at the concentration of 0.5 153 mg/ml. Using a pipette, about 5 µl of the HMGB1-alginate solution was then added to 2 mM 154 CaCl 2 solution in the form of drops, which solidified to form alginate beads. Control alginate 155 beads were prepared without adding HMGB1. The beads were then removed from the CaCl 2 156 solution and allowed to air dry. The final diameter of the beads was around 0.5 mm, which is 157 about 1/6 of the rat patellar tendon width. This protocol was developed in our laboratory (43).
158 159 Sprague Dawley (SD) rats (female, 6 months) were sedated by inhaling 2-3% isoflurane.
160 The skin over the patellar tendon was then shaved, sterilized and a small incision was made on 161 the skin to expose the tendon. HMGB1-alginate beads containing 2.5 µg HMGB1 or blank 162 alginate beads with the same size for control were implanted into the central part of the left and 163 right patellar tendons. After 2 and 4 weeks, 5 rats in each group were used for hematoxylin & 248 normal tendinous tissues without mechanical loading. The Western blot results showed that 249 HMGB1 is present in the patellar and Achilles tendinous tissues, and immunofluorescence 250 results showed that it is localized in the nuclei, not in ECM (S1 Fig) . After treadmill running, 251 Achilles tendon sections of the control group (cage activity only) showed the presence of tendon 252 cells that stained blue with Hoechst 33342, but the tendon matrix was not positively stained 253 indicating the absence of HMGB1 in the matrix (Fig 1A) . The tendinous tissue was cut into 10 254 µm thickness pieces were not penetrated with detergent to minimize staining of HMGB1 in the 255 nucleus (a penetrated tissue staining sample is shown in S1C Fig) . Some peripheral areas that 256 appear red are paratenon, which surrounds the tendon proper (Fig 1A, a, e ). In the tendon 257 sections from mice on the MTR regimen, HMGB1 staining was absent in the tendon matrix 258 except for the mild positive staining in the peripheral areas (Fig 1A, b ). However, a marked 259 increase in HMGB1staining was observed in the mouse tendon matrix with the ITR regimen for 260 3 weeks (Fig 1A, c) . A 20x magnification shows clear positive staining for HMGB1 outside the 261 tendon cells and in the tendon matrix (arrowhead, Fig 1A, g) . The same increasing trend for 262 HMGB1 staining was observed in the tendon matrices of mice 5-7 hrs on the OTR regimen ( Fig   263 1A, d, h) . The majority of HMGB1 is detected surrounding the elongated tendon cells, which 264 indicates HMGB1 is released by these cells.
266
These findings were also confirmed by ELISA measurement of in vivo HMGB1 levels in 267 mouse patellar and Achilles tendon matrices (PT and AT, respectively) subjected to mechanical 268 loading protocols (Fig 1B, C) . Specifically, HMGB1 levels were 6.6-fold higher in Achilles 269 tendon, and 6.8 times higher in patellar tendon of ITR group when compared to the control mice 270 that remained in cages. HMGB1 levels were also significantly higher in the Achilles tendinous 271 tissues of OTR mice and was 3.2-fold higher when compared to the control, while patellar 272 tendon tissues showed a 2.3-fold change compared to control but without statistical significance 273 (Fig 1B, C) . These results indicate that only excessive mechanical loading conditions, ITR and 274 OTR, trigger the release of HMGB1 from the tendon cells into the tendon matrix. In order to 275 confirm that the higher HMGB1 concentration in ITR and OTR groups is not due to massive cell 276 destruction during sample preparation, we measured the total DNA content in all samples, and 277 they were equivalent but significantly lower than total lysed tendon samples (Fig 1D) .
278 Additionally, the in vivo results are supported by in vitro cell mechanical stretching experiments;
279 that is, mechanical overloading induces release of HMGB1 from the tendon cells to the culture 280 media (S2 Fig) .
282 Short term ITR induces inflammatory cell infiltration in tendon 283
To investigate whether intensive mechanical loading induces inflammatory cell 284 infiltration in tendinous tissues, we performed immunostaining of Achilles tendinous tissues after 285 MTR, ITR, and OTR with inflammatory cell marker CD68. CD68 staining was absent in the 286 control and MTR (Fig 2A, B) , but was detected in the Achilles tendon sections of mice on the 287 ITR regimen (Fig 2C) . The induction of inflammatory cell infiltration by ITR implies that 288 HMGB1 may invoke an inflammatory reaction in tendon (arrow heads, Fig 2C) . However, CD68
289 was found negative in OTR regimen (Fig 2D) . Although OTR could induce HMGB1 release 290 within a short period of time (Fig 1A, B) , it may not have sustained long enough to induce any 291 inflammatory cell infiltration unless excessive mechanical loading is repeated for a prolonged 292 period. To confirm the likelihood that HMGB1 causes inflammatory response in tendon, we 294 implanted HMGB1 in alginate beads to rat tendon and immunostained tendon sections for CD68 295 and CD31 after 2 and 4 weeks. The H&E stain of control tendon implanted with blank beads 296 shows no cell proliferation (Fig 2E, a) , while tendon section with implanted HMGB1 beads 297 shows extensive cell proliferation (highlighted in the blue box) after 2 weeks (Fig 2E, b) . The 298 implantation site after 4 weeks showed higher number of cells (Fig 2E, c, arrow) compared to 299 control, but is much less compared to the 2 weeks group. Control did not show positive IHC 300 stains for CD68 (Fig 2E, d) , but positive CD68 staining in HMGB1 implanted sample for 2 301 weeks showed inflammatory cell infiltration (Fig 2E, e, arrows) . The four weeks implantation 302 group showed minimal positive staining for CD68 (Fig 2E, f) . Moreover, implantation of 303 HMGB1 beads at two weeks resulted in the formation of vessel-like structures (Fig 2F, a, 304 arrows). Positive IHC staining for CD31 reveals extensive angiogenesis in the group (Fig 2F, b, 305 arrow). Collectively, these data show that under prolonged repetitive mechanical overloading 306 conditions (ITR), HMGB1 is released into the Achilles and patellar tendon matrix, leading to 307 hypercellularity, inflammatory cell infiltration, and angiogenesis in tendon.
308 309 GL blocks HMGB1-induced tendon inflammation in vivo 310 To determine whether GL can negate the inflammatory effects of HMGB1 released to 311 tendon matrix by the short term ITR regimen (3 weeks), we administrated GL to mice by IP 312 injection on the ITR regimen 15 min before they started the treadmill running. Prior to this assay, 313 we determined whether injected GL can be transported and remain in the tendon region after 314 injections. Quantification of GL using thin layer chromatography 3 hrs after injection showed 315 significant levels of GL in mouse patellar and Achilles tendons (S3 Fig) . GL injection into 338 B). Normal tendon cells in control group are tightly packed in the collagen tissue are largely 339 spindle shaped (Fig 4A, a-c) . However, many of the cells in Lt-ITR mouse Achilles tendon were 340 round with lacunae around the cells, which is a typical chondrocyte appearance (Fig 4A, d-f ).
341 Semi-quantification of the percentage of round cells near the end site of Achilles tendon showed 342 around 30% of cells are round with cartilage lacunae (Fig 4A, g) . Also, there is minimal GAG in 343 the normal tendon (Fig 4A, a-c) , while Lt-ITR induced significant GAG accumulation (Fig 4A,   344 d-f) . Additionally, there were no round cells or SOX-9 staining in the control (Fig 4B, a, b) , 345 while some of those round shaped cells in Lt-ITR mouse tendon were positive for SOX-9 ( Fig   346 4B, c, d) . Semi-quantification revealed that about 20% of the cells in 12-week Lt-ITR mouse 347 tendons near the insertion site were positive for SOX-9 (Fig 4B, e) . 358 GL inhibitory effect, we divided the Achilles tendon near the insertion site into two areas, the 359 proximal region (~300 µm from the end of tendon tissue), which belongs to Achilles tendinous 360 tissue (Figs 5, 6, yellow boxes) , and the distal region (Figs 5, 6 , green boxes) next to the tendon-361 bone insertion, which is very near the end of the tendon tissue that is considered as part of 362 transitional zone between tendon and heel bone. We found that a small number of chondrocyte-363 like cells exist in the distal region in the control group. With this in mind, we focused on the 364 proximal region since it represents the site of degenerative changes in tendon rather than the 365 region of possible pre-existing chondrocyte-like cells.
367
We found that after 24 weeks of Lt-ITR, the proximal site of Achilles tendon contained 368 cells with round shape (arrowheads in Fig 5A, g) , compared to more elongated cells in the cage 369 control and GL treatment group alone groups (Fig 5A, e, f) . However, in Lt-ITR mice treated 370 with daily injection of GL, no change in cell shape was observed (Fig 5A, h) . In addition, in 371 these Lt-ITR mice, extensive GAG staining in the tendon was present. Such GAG accumulation 372 was prevented by GL administration in the group (Fig 5B, bottom panel) . Also, Lt-ITR induced 373 the expression of chondrogenic markers (SOX-9 and Col II) in Achilles tendon, and GL inhibited 374 the expression of SOX-9 and Col II confirmed by immunofluorescence staining (Fig 6A, B (15, 17) . A few other studies have shown that upregulation of 387 HMGB1 is associated with shoulder tendon injury/tendinopathy in patients and indicated that it 388 would be a valuable target for tendinopathy management (37-39, 47). In this study, we extend 389 these investigations to examine the role of HMGB1, an inflammatory alarmin molecule, in 390 tendinopathy development due to mechanical overloading conditions. We show that HMGB1 is 391 released to the extracellular space of tendon cells under mechanical overloading conditions 392 thereby eliciting the cells' inflammatory and catabolic responses marked by elevated PGE 2 , and 393 MMP-3 production in a rodent model. Moreover, we show that by daily IP injection, GL reduces 394 the inflammatory/catabolic reactions marked by high levels of production in PGE 2 and MMP-3, 395 in overloaded mouse tendons in vivo. Finally, GL administration in mice that underwent long 396 term intensive treadmill running blocks the development of degenerative tendinopathy 397 characterized by the presence of chondrocyte-like cells, accumulation of proteoglycans, 398 chondrogenic marker SOX-9 expression, and high levels of collagen type II production.
400
Although the presence of inflammation in tendinopathic tendons is highly debated, the 401 contribution of immune cells and inflammatory mediators to tendinopathy development are 402 increasingly recognized. Recent investigations in human tissues and cells from tendinopathic 403 patients strongly support that inflammation is involved in tendinopathy (11-13). Infiltration of 404 inflammatory cells like macrophages and mast cells has been reported in early supraspinatus 405 tendinopathy patients (11). Tendinopathy may not progress through a classic inflammatory 429 therapeutic in arthritis, because administration of either anti-HMGB1 or A-box of HMGB1 in 430 collagen type II-induced arthritis significantly attenuated the severity of disease (50). Thus, 431 HMGB1 may represent a new target of therapy of inflammation-related diseases such as 432 tendinopathy. This is supported by the finding that use of GL, a specific inhibitor of HMGB1, 433 suppresses inflammatory responses as defined by PGE 2 in tendon cells and prevents 434 tendinopathy development.
436
In this study, HMGB1 was shown to be released into tendon matrix in response to 437 mechanical overloading conditions (ITR). But the exact "release modes" are not clear. The 438 HMGB1 may be actively released by tendon cells due to excessive mechanical stress on the 439 cells, as suggested by in vitro data of this study; or it may be from passive release by loading-440 induced cellular necrosis. Additionally, macrophage/monocytes recruited to tendon tissue during 441 overloading may also release HMGB1. All "release modes," would lead to inflammatory 442 responses in tendon matrix.
444
It is known that HMGB1 acts as a chemoattractant in various cell types like 445 macrophages, neutrophils, mesoangioblasts, and osteoclasts (33, 34). Our study also 446 demonstrates this well-known property of HMGB1 in tendons. After initial tendon microinjury 447 by repetitive mechanical over loading such as long-term intensive treadmill running in this study, 448 inflammation can occur with influx of white blood cells, and HMGB1 by its chemoattractant 449 property may recruit neutrophils, monocytes, and macrophages to sites of injury. While 450 exploring the HMGB1 effect in vitro, we found that this mediator did promote tendon cell 451 migration and inflammatory reactions but did not induce their proliferation (data not shown).
452 Interestingly, in the HMGB1 implantation experiment, HMGB1 induced hypercellularity in 453 tendon tissues (Fig 2E) . It is likely that HMGB1 exerts its function by recruiting inflammatory 454 cells to the "injury site", and then initiates the release of cytokines (e.g. IL-6, IL-1β, IL-6, and 455 IL-8) from the inflammatory cells. This should be investigated in future studies.
457
In this study, we used GL to inhibit HMGB1-induced inflammation as defined by PGE 2 458 in contrast to inflammatory markers such as IL-1β, IL-6, and IL-8 , since clinically, inflammation 459 reduction is achieved by using non-steroidal anti-inflammatory drugs (NSAIDs), which inhibit 460 COX and as a result, reduce PGE 2 . Moreover, the amplification of the PGE 2 biosynthesis 461 pathway by HMGB1/IL-1β is suggested as an important pathogenic mechanism perpetuating 462 inflammatory and destructive activities in rheumatoid arthritis (51).While it is currently unclear 463 whether our findings will reflect the actual mechanisms of tendinopathy development and 464 treatment in humans, recent studies demonstrated that HMGB1 is present in human 465 tendinopathic tendons and regulates cellular inflammation and protein production in vitro (37, 466 38). This suggests that HMGB1 plays a similar role in the development of tendinopathy due to 467 mechanical overloading.
469
The specific inhibitor of HMGB1, glycyrrhizin (GL), is a natural glyco-conjugated 470 triterpene present in licorice plant. It blocks prostaglandin production and inflammation (52).
471 Topically, it has been in use for the treatment of tendinitis, bursitis, and gum inflammation. It has 472 been used in preclinical investigations to inhibit HMGB1 signaling to treat inflammation in lung 473 and liver diseases (42). GL has a long history of well-known anti-inflammatory effects (53-55), 474 and studies show that it can inhibit the chemoattractant and mitogenic activity of HMGB1 by 475 direct binding (52, 56). It has also been administered to patients with hepatitis B and C and is 476 considered to be safe for human consumption (52, 57, 58), but GL may have off-target effects 477 other than inhibition of HMGB1. The side effect of GL is mainly from its metabolic product 478 glycyrrhetic acid after oral ingestion and catalyzed by bacteria in gut(59), which is irrelevant to 479 IP injection of GL that we used in this study. Therefore, GL is safe for in vivo use and has 480 minimal off-target effects when IP injection is used for GL delivery. In conclusion, our results support that HMGB1 released to tendon matrix due to 500 mechanical overloading induces tendinopathy development by initiation of tendon inflammation 501 and eventual tendon degeneration. These results provide evidence for the role of HMGB1 as a 502 therapeutic target to prevent tendinopathy before its onset and block further development at its 503 early inflammation stages. The inhibition of tendinopathy development by GL administration in 504 this study also suggests that GL may be used as a therapeutic agent to prevent tendinopathy 505 development. 
